A Study of HIPEC Plus Apatinib and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells

NCT03428425 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: paclitaxel apatinib S-1

Sponsor

Hebei Medical University